Hypertension and cardiac disease are common consequences of aging. Unfortunately, many elderly individuals do not respond to current therapies for reducing blood pressure, and the factors that drive age-related hypertension are poorly understood. In this issue of JCI Insight, researchers led by Iris Jaffe of Tufts Medical Center provide evidence that age-related reductions of a microRNA (miR-155) underlie age-associated hypertension. Mice that lack mineralocorticoid receptors in smooth muscle cells, which regulate blood pressure, are protected from developing high blood pressure as they age. Jaffe and colleagues determined that compared to aged wild type mice, aged animals lacking mineralocorticoid receptors have elevated levels of miR-155, less oxidative stress, and fewer hypertensive characteristics. Moreover, restoration of miR-155 in aged wild type mice improved blood pressure parameters. Importantly, in a small cohort of healthy older adults treated with a mineralocorticoid receptor inhibitor, reduced levels of miR-155 were associated with beneficial changes in blood pressure. Together, these results indicate that miR-155 should be further explored as a biomarker and therapeutic target for age-related hypertension.
Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging
Tufts Medical Center
Email: [email protected]
View this article at: http://insight.jci.org/articles/view/88942?key=3960d19850eec679d770
JCI Insight is the newest publication from the American Society of Clinical Investigation, a nonprofit honor organization of physician-scientists. JCI Insight is dedicated to publishing a range of translational biomedical research with an emphasis on rigorous experimental methods and data reporting. All articles published in JCI Insight are freely available at the time of publication. For more information about JCI Insight and all of the latest articles go to http://www.insight.jci.org.